Journal of Hepatology, 1990; 11: 401–404
Elsevier

Author Index (Vol. 11)

Anciaux, M.L., see Pelletier, G., 181
Abbiati, R., see Marchesini, G., 92
Adams, D.A., see Neuberger, J.M., 1
Alberti, A., see Fattovich, G., 29
Allman, K.-H., see Rieder, H., 359
Amouretti, M., see Chazouillères, O., 120
Arroyo, V. and Ginés, P., Prostaglandins and the treatment of hepatorenal syndrome in cirrhosis, 142
Attali, P., see Pelletier, G., 181

Bachem, M.G., see Meyer, D.H., 86
Bacq, Y., Roulot, D., Braillon, A. and Lebrec, D., Hemodynamic effects of dopamine in conscious rat with secondary biliary cirrhosis, 257
Ballardini, G., see Jezequel, A.M., 206
Ballet, F., see Panis, Y., 53
Bartolomé, J., see Madejón, A., 381
Bauer, J., see Busam, K.J., 367
Bauer, T.M., see Busam, K.J., 367
Bellati, G., see Marchesini, G., 92
Benhamou, J.-P., see Marcellin, P., 77
Benhamou, J.P., see Zignego, A.L., 102
Benichou, C., Criteria of drug-induced liver disorders. Report of an International Consensus Meeting, 272
Berthelot, P., see Pol, S., 385
Bianchi, F.B., see Jezequel, A.M., 206
Bianchi, G.P., see Marchesini, G., 92
Bingen, A., see De Craemer, D., 145
Binoux, M., see Cariani, E., 226
Bismuth, A., see Zignego, A.L., 102
Bismuth, H., see Zignego, A.L., 102
Bolondi, L., see Buscarini, L., 344
Bomzon, A., Weinbroum, A. and Kamenetz, L., Systemic hypotension and pressor responsiveness in cholestasis. A study in conscious 3-day bile duct ligated rats, 70
Bosch, J., see Garcia-Pagán, J.C., 189
Boyer, N., see Marcellin, P., 77
Braillon, A., see Bacq, Y., 257
Braunwald, J., see Chen, W., 330
Brechot, C., see Cariani, E., 226
Brollo, L., see Fattovich, G., 29
Brouwer, A., Hendriks, H.F.J. and Knook, D.L., The role of eicosanoids in the acute phase response, 283
Bru, C., see Garcia-Pagán, J.C., 189
Bréchot, C., Polymerase chain reaction. A new tool for the study of viral infections in hepatology, 124
Bréchot, C., see Zignego, A.L., 102
Burroughs, A.K., see McCormick, P.A., 221
Busam, K.J., Bauer, T.M., Bauer, J., Gerok, W. and Decker, K., Interleukin-6 release by rat liver macrophaged, 367
Buscarini, L., Fornari, F., Bolondi, L., Colombo, P., Livraghi, T., Magnolfi, F., Rapaccini, G.L. and Salmi, A., Ultrasound-guided fine-needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications, 344

Cadafalch, J., see López-Navidad, A., 277
Callender, M.E., see McClements, B.M., 322
Campillo, M.L., see Madejón, A., 381
Capron, J.-P., see Chazouillères, O., 120
Car, B.I. and Van Thiel, D.H., Hormonal manipulation of human hepatocellular carcinoma, 287
Cariani, E., Seurin, D., Lasserre, C., Franco, D., Binoux, M. and Brechot, C., Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis, 226
Carreño, V., see Madejón, A., 381
Casini, A., Lippe, I.Th., Evangelista, S., Geppetti, P., Santicioli, P., Urso, C., Paglierani, M., Maggi, C.A. and Surrenti, C., Effect of sensory denervation with capsaicin on liver fibrosis induced by common bile duct ligation in rat, 302
Castillo, I., see Madejón, A., 381
Chazouillères, O., Poupon, R., Capron, J.-P., Metman, E.-H., Dhumeaux, D., Amouretti, M., Couzigou, P., Labayle, D. and Trinchet, J.-C., Ursodeoxycholic acid for primary sclerosing cholangitis, 120
Chen, W., Steffan, A.-M., Braunwald, J., Nonnemacher, H., Kirn, A. and Gendrault, J.-L., Inhibition in fat-storing cell multiplication by a factor produced by normal cultured murine hepatocytes, 330
Chiandussi, L., see Saracco, G., 339
Chiaramonte, M., see Farinati, F., 297
Chun, Y.B., Miyauchi, S., Sugiyama, Y., Harashima, H., Iga, T. and Hanano, M., Effect of various organic anions on the plasma disappearance of 1-anilino-8-naphthalene sulfonate, 240
Colombo, P., see Buscarini, L., 344
Cossu, P.A., see Saracco, G., 339
Coulton, L., see Watson, R.G.P., 354
Couzigou, P., see Chazouillères, O., 120
Čuperlović, M., see Nikolić, J.A., 252

Davidson, B.R., Varsamidakis, N., Scheuer, P. and Hobbs, K., Fibrolamellar carcinoma arising in an abnormal liver, 388
De Cotiis, R., see Salmi, A., 279
De Craemer, D., Bingen, A., Langendries, M., Martin, J.-P. and Roels, F., Alterations of hepatocellular peroxisomes in viral hepatitis in the mouse, 145
De Groote, J., see Fevery, J., 153
De Groote, J., see Nevens, F., 80
De Maeyer, M.H., see Michielsen, P.P., 392
De Man, R.A., Wilson, J.H.P., Schalm, S.W., Ten Kate, F.J.W. and Van Leer, E., Phenprocoumon-induced hepatitis mimicking non-A, non-B hepatitis, 318
De Maria, N., see Farinati, F., 297
De Micheli, A.G., see Saracco, G., 339
Decker, K., see Busam, K.J., 367
Del Vecchio, S., Ulissi, A., Tavanti, A., Delle Monache, M., Munoz, M.E., Ventura, P., Schiavi, A. and Ricci, G.L., Changes in the plasma clearance of antipyrine after treatment of healthy male volunteers with epomodial, 391
Delelo, R., see Panis, Y., 53
Delle Monache, M., see Del Vecchio, S., 391
Dény, P., Nicolas, J.-C., Loiseau, D. and Lefrère, J.-J., Prevalence of antibodies to hepatitis C in different causes of cirrhosis, 393
Deplano, A., see Saracco, G., 339
Derhy, S., see Pelletier, G., 181
Desmet, V., see Nevens, F., 80
Desmet, V.J., see Van Eyken, P., 43
Dhumeaux, D., see Chazouillères, O., 120
Dhumeaux, D., see Genève, J., 196
Dick, R., see McCormick, P.A., 221
Dioguardi, F.S., see Marchesini, G., 92
Dollery, C.T., see Moore, K.P., 263
Domingo, P., see López-Navidad, A., 277
Donegani, E., see Saracco, G., 339
Dubois, F., see Zignego, A.L., 102
Dubuc, N., see Genève, J., 196
Dumont, M., see Perez Barriocanal, F., 165
Durazzo, M., see Saracco, G., 339

Elias, E., see Iqbal, S., 37
Elias, E., see Watson, R.G.P., 354
Erlinger, S., see Perez Barriocanal, F., 165
Eschwège, E., see Poupon, R.E., 16
Etienne, J.-P., see Pelletier, G., 181
Evangelista, S., see Casini, A., 302

Farinati, F., Salvagini, M., De Maria, N., Fornasiero, A., Chiaramonte, M., Rossaro, L. and Naccarato, R., Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen, 297
Farrerons, J., see López-Navidad, A., 277
Fattovich, G., Brollo, L., Alberti, A., Giustina, G., Pontisso, P., Realdi, G. and Ruol, A., Chronic persistent hepatitis type B can be a progressive disease when associated with sustained virus replication, 29
Feu, F., see Garcia-Pagán, J.C., 189
Fevery, J., Van Cutsem, E., Nevens, F.,

Van Steenberger, W., Verbeckmoes, R. and De Groote, J., Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration, 153
Fevery, J., see Nevens, F., 80
Fevery, J., see Sieg, A., 159
Fitzke, E., see Senn, H.-J., 290
Fornari, F., see Buscarini, L., 344
Fornasiero, A., see Farinati, F., 297
Franco, D., see Cariani, E., 226
Friman, S., Leandersson, P., Tagesson, C. and Svanvik, J., Biliary excretion of different sized polyethylene glycols in the cat, 215
Fuller, R.W., see Moore, K.P., 263

Gallo, V., see Saracco, G., 339
Garcia-Pagán, J.C., Feu, F., Navasa, M., Bru, C., Ruiz del Arbol, L., Bosch, J. and Rodés, J., Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension, 189
Gendrault, J.-L., see Chen, W., 330
Gentilini, P., see Zignego, A.L., 102
Genève, J., Dubuc, N., Mathieu, D., Zafrani, E.S., Dhumeaux, D. and Métreau, J.-M., Cystic dilatation of intrahepatic bile ducts in primary sclerosing cholangitis, 196
Georgopoulou, U., see Zignego, A.L., 102
Geppetti, P., see Casini, A., 302
Gerken, G., see Wächter, B., 232
Gerok, W., see Busam, K.J., 367
Gerok, W., see Senn, H.-J., 290
Gerok, W., see Weiler, H., 58
Ginés, P., see Arroyo, V., 142
Giostra, E., see Marcellin, P., 77
Giustina, G., see Fattovich, G., 29
Glauman, H., see Stål, P., 172
Golubović, G., see Nikolić, J.A., 252
Graffeo, M., see McCormick, P.A., 221
Gressner, A.M., see Meyer, D.H., 86

Hadziyannis, S.J., see Zignego, A.L., 102
Hajduković, L., see Nikolić, J.A., 252
Hanano, M., see Chung, Y.B., 240
Harashima, H., see Chung, Y.B., 240
Haukenes, G., Matre, R., Tønder, O., Myrmel, H. and Schrumpf, E., Measles and rubella antibodies in patients with chronic liver disease, 389
Hendriks, H.F.J., see Brouwer, A., 283
Herve, J.P., see Panis, Y., 53
Hobbs, K., see Davidson, B.R., 388
Hultcrantz, R., see Stål, P., 172
Höckerstedt, K. and Lautenschlager, I., The histological picture of graft rejection following liver transplantation, 130

Iga, T., see Chung, Y.B., 240
Infante, O., see Panis, Y., 53
Ink, O., see Pelletier, G., 181
Iqbal, S., Vickers, C. and Elias, E., Drug metabolism in end-stage liver disease. In vitro activities of some phase I and phase II enzymes, 37
Ishikawa, M., see Togashi, H., 200
Ishizaka, S., Kuriyama, S., Kikuchi, E., Nishimura, K. and Tsujii, T., A novel oral adjuvant for hepatitis B virus (HBV) vaccines, 326

James, O.F.W., Ursodeoxycholic acid treatment for chronic cholestatic liver disease, 5
Jezequel, A.M., Ballardini, G., Mancini, R., Paolucci, F., Bianchi, F.B. and Orlandi, F., Modulation of extracellular matrix components during dimethylnitrosamine-induced cirrhosis, 206
Johnson, P.J., see Kalayci, C., 349

Kalayci, C., Johnson, P.J., Raby, N., Metivier, E.M. and Williams, R., Intraarterial adramycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin, 349
Kamenetz, L., see Bomzon, A., 70
Kanis, J.A., see Watson, R.G.P., 354
Karpouza, A., see Parquet, M., 111
Kikuchi, E., see Ishizaka, S., 326
Kirn, A., see Chen, W., 330
Knook, D.L., see Brouwer, A., 283
Kreis, H., see Pol, S., 385
Kuhnle, M., see Panis, Y., 53
Kuriyama, S., see Ishizaka, S., 326
Kyriatsoulis, A., see Wächter, B., 232
König, R., see Sieg, A., 159
Köster, W., see Senn, H.-J., 290

Labayle, D., see Chazouillères, O., 120
Langendries, M., see De Craemer, D., 145
Lasserre, C., see Cariani, E., 226
Laub, O., see Tur-Kaspa, R., 34
Lautenschlager, I., see Höckerstedt, K., 130
Leandersson, P., see Friman, S., 215
Lebrec, D., see Bacq, Y., 257
Lefrère, J.-J., see Dény, P., 393
Legendre, Ch., see Pol, S., 385
Legrand-Defretin, V., see Parquet, M., 111
Lenoir, C., see Pelletier, G., 181
Lippe, I.Th., see Casini, A., 302
Livraghi, T., see Buscarini, L., 344
Loiseau, D., see Dény, P., 393
Lombard, M., see Watson, R.G.P., 354
Loriot, M.-A., see Marcellin, P., 77
Lose, A.W., see Wächter, B., 232
Lutton, C., see Parquet, M., 111
López-Navidad, A., Domingo, P., Cadafalch, J. and Farrerons, J., Norfloxacin-induced hepatotoxicity, 277

Madden, A., see McCormick, P.A., 221
Madejón, A., Castillo, I., Bartolomé, J., Melero, M., Campillo, M.L., Porres, J.C., Moreno, A. and Carreño, V., Detection of HDV-RNA by PCR in serum of patients with chronic HDV infection, 381
Maggi, C.A., see Casini, A., 302
Magnolfi, F., see Buscarini, L., 344
Maltby, N.H., see Moore, K.P., 263
Mancini, R., see Jezequel, A.M., 206
Manns, M., see Wächter, B., 232
Marcellin, P., Giostra, E., Boyer, N., Loriot, M.-A., Martinot-Peignoux, M. and Benhamou, J.-P., Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis?, 77
Marchesini, G., Dioguardi, F.S., Bianchi, G.P., Zoli, M., Bellati, G., Roffi, L., Martines, D. and Abbiati, R., Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial, 92
Marin, J.J.G., see Perez Barriocanal, F., 165
Martin, J.-P., see De Craemer, D., 145
Martines, D., see Marchesini, G., 92
Martinot-Peignoux, M., see Marcellin, P., 77
Mathieu, D., see Genève, J., 196
Matre, R., see Haukenes, G., 389
Mattlinger, B., see Pol. S., 385
McClements, B.M. and Callender, M.E., D-Penicillamine therapy in patients with HBsAg-negative chronic active hepatitis and major prednisolone-induced adverse effects, 322
McCormick, P.A., Dick, R., Graffeo, M., Wagstaff, D., Madden, A., McIntyre, N. and Burroughs, A.K., The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis, 221
McIntyre, N., see McCormick, P.A., 221
Melero, M., see Madejón, A., 381
Metivier, E.M., see Kalayci, C., 349
Metman, E.-H., see Chazouillères, O., 120
Meyer zum Büschenfelde, K.-H., see Wächter, B., 232
Meyer zum Büschenfelde, K.-H., see Rieder, H., 359
Meyer, D.H., Bachem, M.G. and Gressner, A.M., Transformed fat storing cells inhibit the proliferation of cultured hepatocytes by secretion of transforming growth factor beta, 86
Michielsen, P.P., Van Outryve, M.J., Van Marck, E.A., De Maeyer, M.H., Pelckmans, P.A. and Van Maercke, Y.M., Amoxycillin/clavulanic acid induced cholestasis, 392
Millward, S.E., see Rutishauser, S.C.B., 22
Miyauchi, S., see Chung, Y.B., 240
Moore, K.P., Taylor, G.W., Maltby, N.H., Siegers, D., Fuller, R.W., Dollery, C.T. and Williams, R., Increased production of cysteinyl leukotrienes in hepatorenal syndrome, 263
Moreno, A., see Madejón, A., 381
Morgan, M.Y., Branched chain amino acids in the management of chronic liver didease. Facts and fantasies, 133
Munoz, M.E., see Del Vecchio, S., 391

Myrmel, H., see Haukenes, G., 389
Métreau, J.-M., see Genève, J., 196

Naccarato, R., see Farinati, F., 297
Nakamura, A.T., see Togashi, H., 200
Nakata, K., see Shibayama, Y., 313
Navasa, M., see Garcia-Pagán, J.C., 189
Neuberger, J., see Watson, R.G.P., 354
Neuberger, J.M. and Adams, D.A., Is HLA matching important for liver transplantation?, 1
Nevens, F., Fevery, J., Van Steenbergen, W., Sciot, R., Desmet, V. and De Groote, J., Arsenic and non-cirrhotic portal hypertension. A report of eight cases, 80
Neves, F., see Fevery, J., 153
Nicolas, J.-C., see Dény, P., 393
Nikolić, J.A., Stajić, M., Čuperlović, M., Hajduković, L. and Golubović,G., Serum α-fetoprotein levels and microheterogeneity in patients with different liver diseases, 252
Nishimura, K., see Ishizaka, S., 326
Nomura, F., Ohnishi, K. and Ohto, M., Detection of malotilate toxicity in vitro with peripheral blood mononuclear cell as targets. A preliminary report, 65
Nonnemacher, H., see Chen, W., 330
Nordlinger, B., see Panis, Y., 53

Ohnishi, K., see Nomura, F., 65
Ohto, M., see Nomura, F., 65
Orlandi, F., see Jezequel, A.M., 206
Orth, M., see Senn, H.-J., 290

Paglierani, M., see Casini, A., 302
Panis, Y., Nordlinger, B., Delelo, R., Herve, J.P., Infante, J., Kuhnle, M. and Ballet, F., Experimental colorectal liver metastases. Influence of sex, immunological status and liver regeneration, 53
Paolucci, F., see Jezequel, A.M., 206
Parquet, M., Legrand-Defretin, V., Riottot, M., Karpouza, A. and Lutton, C., Metabolism and effects on biliary lipid secretion of murocholic acid in the hamster, 111
Pelckmans, P.A., see Michielsen, P.P., 392
Pelletier, G., Roche, A., Ink, O., Anciaux, M.L., Derhy, S., Rougier, P., Lenoir, C., Attali, P. and Etienne, J.-P., A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma, 181
Perez Barriocanal, F., Marin, J.J.G., Dumont, M. and Erlinger, S., Influence of backward perfusion on ursodeoxycholate-induced choleresis in isolated in situ rat liver, 165
Petrino, R., see Saracco, G., 339
Pintus, C., see Saracco, G., 339
Pol, S., Legendre, Ch., Mattlinger, B., Berthelot, P. and Kreis, H., Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients, 385
Pontisso, P., see Fattovich, G., 29
Porres, J.C., see Madejón, A., 381
Poupon, R., see Chazouillères, O., 120
Poupon, R., see Poupon, R.E., 16
Poupon, R.E., Eschwège, E. and Poupon, R., Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial, 16

Raby, N., see Kalayci, C., 349
Raimondo, G., Stemler, M., Schneider, R., Wildner, G., Squadrito, G. and Will, H., Latency and reactivation of precore mutant hepatitis B virus in a chronically infected patient, 374
Ramadori, G., see Rieder, H., 359
Rapaccini, G.L., see Buscarini, L., 344
Realdi, G., see Fattovich, G., 29
Reynes, M., see Zignego, A.L., 102
Ricci, G.L., see Del Vecchio, S., 391
Rieder, H., Ramadori, G., Allman, K.-H. and Meyer zum Büschenfelde, K.-H., Prostanoid release of cultured liver sinusoidal endothelial cells in response to endotoxin and tumor necrosis factor. Comparison with umbilical vein endothelial cells, 359
Riottot, M., see Parquet, M., 111
Rizzetto, M., see Saracco, G., 339
Roche, A., see Pelletier, G., 181
Rodés, J., see Garcia-Pagán, J.C., 189
Roels, F., see De Craemer, D., 145
Roffi, L., see Marchesini, G., 92
Rosina, F., see Saracco, G., 339
Rossaro, L., see Farinati, F., 297
Rougier, P., see Pelletier, G., 181
Roulot, D., see Bacq, Y., 257
Ruiz del Arbol, L., see Garcia-Pagán, J.C., 189
Ruol, A., see Fattovich, G., 29
Rusconi, C., see Salmi, A., 279
Rutishauser, S.C.B. and Millward, S.E., The effects of hypertonic glucose solutions on hepatic bile formation, 22

Sallie, R., Diclofenac hepatitis, 281
Salmi, A., De Cotiis, R. and Rusconi, C., On the rarity of Cruveilhier-Baumgarten's venous hum, 279
Salmi, A., see Buscarini, L., 344
Salvagini, M., see Farinati, F., 297
Samuel, D., see Zignego, A.L., 102
Santicioli, P., see Casini, A., 302
Saracco, G., Touscoz, A., Durazzo, M., Rosina, F., Donegani, E., Chiandussi, L., Gallo, V., Petrino, R., De Micheli, A.G., Solinas, A., Deplano, A., Tocco, A., Cossu, P.A., Pintus, C., Verme, G. and Rizzetto, M., Autoantibodies and response to α-interferon in patients with chronic viral hepatitis, 339
Schalm, S.W., see De Man, R.A., 318
Scheuer, P., see Davidson, B.R., 388
Schiavi, A., see Del Vecchio, S., 391
Schneider, R., see Raimondo, G., 374
Schölmerich, J., see Senn, H.-J., 290
Schrumpf, E., see Haukenes, G., 389
Sciot, R., see Nevens, F., 80
Sciot, R., see Van Eyken, P., 43
Senn, H.-J., Orth, M., Fitzke, E., Schölmerich, J., Köster, W., Wieland, H. and Gerok, W., Altered concentrations, patterns and distribution in lipoproteins of serum gangliosides in liver diseases of different etiologies, 290
Seurin, D., see Cariani, E., 226
Shibayama, Y. and Nakata, K., The relation of periportal fibrosis to portal hypertension, 313
Shinzawa, H., see Togashi, H., 200
Sieg, A., König, R., Ulrich, D. and Fevery, J., Subfractionation of serum bilirubins by alkaline methanolysis and thin-layer chromatography. An aid in the differential diagnosis of icteric diseases, 159
Siegers, D., see Moore, K.P., 263
Solinas, A., see Saracco, G., 339
Squadrito, G., see Raimondo, G., 374
Stajić, M., see Nikolić, J.A., 252
Steffan, A.-M., see Chen, W., 330
Steinhoff, G., Major histocompatibility complex antigens in human liver transplants, 9
Stemler, M., see Raimondo, G., 374
Stål, P., Glaumann, H. and Hultcrantz, R., Liver cell damage and lysosomal iron storage in patients with idiopathic hemochromatosis. A light and electron microscopic study, 172
Sugiyama, Y., see Chung, Y.B., 240
Surrenti, C., see Casini, A., 302
Svanvik, J., see Friman, S., 215

Tagesson, C., see Friman, S., 215
Takahaski, T., see Togashi, H., 200
Tavanti, A., see Del Vecchio, S., 391
Taylor, G.W., see Moore, K.P., 263
Ten Kate, F.J.W., see De Man, R.A., 318
Tocco, A., see Saracco, G., 339
Togashi, H., Shinzawa, H., Wakabayashi, H., Nakamura, A.T., Yamada, N., Takahashi, T. and Ishikawa, M., Activities of free oxygen radical scavenger enzymes in human liver, 200
Tønder, O., see Haukenes, G., 389
Touscoz, A., see Saracco, G., 339
Trinchet, J.-C., see Chazouillères, O., 120
Tsujii, T., see Ishizaka, S., 326
Tur-Kaspa, R. and Laub, O., Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system, 34

Ulissi, A., see Del Vecchio, S., 391
Ullrich, D., see Sieg, A., 159
Urso, C., see Casini, A., 302

Van Cutsem, E., see Fevery, J., 153
Van Ditzhuijsen, Th.J.M., Van Haelst, U.J.G.M., Van Dooren-Greebe, R.J., Van de Kerkhof, P.C.M. and Yap, S.H., Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acetretin), 185
Van Dooren-Greebe, R.J., see Van Ditzhuijsen, Th.J.M., 185

Van Eyken, P., Sciot, R. and Desmet, V.J., Expression of the novel extracellular matrix component tenascin in normal and diseased human liver. An immunohistochemical study, 43
Van Haelst, U.J.G.M., see Van Ditzhuijsen, Th.J.M., 185
Van Leer, E., see De Man, R.A., 318
Van Maercke, Y.M., see Michielsen, P.P., 392
Van Marck, E.A., see Michielsen, P.P., 392
Van Outryve, M.J., see Michielsen, P.P., 392
Van Steenbergen, W., see Nevens, F., 80
Van Steenberger, W., see Fevery, J., 153
Van Thiel, D.H., see Car, B.I., 287
Van de Kerkhof, P.C.M., see Van Ditzhuijsen, Th.J.M., 185
Varsamidakis, N., see Davidson, B.R., 388
Ventura, P., see Del Vecchio, S., 391
Verbeckmoes, R., see Fevery, J., 153
Verme, G., see Saracco, G., 339
Vickers, C., see Iqbal, S., 37

Wächter, B., Kyriatsoulis, A., Lose, A.W., Gerken, G., Meyer zum Büschenfelde, K.-H. and Manns, M., Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies, 232
Wagstaff, D., see McCormick, P.A., 221
Wakabayashi, H., see Togashi, H., 200
Watson, R.G.P., Coulton, L., Kanis, J.A., Lombard, M., Williams, R., Neuberger, J. and Elias, E., Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporin, 354
Weiler, Ch., see Weiler, H., 58
Weiler, H., Weiler, Ch. and Gerok, W., Gastric mucosal prostaglandin E2 levels in cirrhosis and portal hypertension, 58
Weinbroum, A., see Bomzon, A., 70
Wieland, H., see Senn, H.-J., 290
Wildner, G., see Raimondo, G., 374
Will, H., see Raimondo, G., 374
Williams, R., see Kalayci, C., 349
Williams, R., see Moore, K.P., 263
Williams, R., see Watson, R.G.P., 354
Wilson, J.H.P., see De Man, R.A., 318

Yamada, N., see Togashi, H., 200
Yap, S.H., see Van Ditzhuijsen, Th.J.M., 185

Zafrani, E.S., see Genève, J., 196
Zignego, A.L., Dubois, F., Samuel, D., Georgopoulou, U., Reynes, M., Gentilini, P., Bismuth, A., Benhamou, J.-P., Hadziyannis, S.J., Bismuth, H. and Bréchot, C., Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients, 102
Zoli, M., see Marchesini, G., 92

Journal of Hepatology, 1990; 11: 405–406
Elsevier

Subject Index (Vol. 11)

Acute delta hepatitis, 102
Adriamycin, 349
Adverse drug reaction, 272
Adverse effect, 322
Amino acid, 133
Androgen, 287
e-Antigen, 374
Anti-HBe, 29
–, 374
Anti-HBS, 326
Anti-HCV, 77
Anti-SCA, 232
Antibody response, 326
Antiestrogen hormone, 297
Arsenic, 80
Arterial pressure, 257
Ascite, 263
Autoantibody, 232
Autoimmune (CAH), 322
Autoimmunity, 232
Azygos blood flow, 189

Bicarbonate secretion, 165
Bile acid, 111
–, 120
–, 165
Bile flow, 165
–, 215
Bile secretion, 22
–, 215
Biliary lipid secretion, 111
Bilirubin, 159
Biopsy, 344
Branched-chain amino acid, 92
–, 133

Canaliculi, 215
Cancer chemotherapy, 297
Cancer therapy, 287
Capsaicin, 302
Cardiovascular function, 70
Caroli's disease, 196
Casualty assessment, 272
Catalase cytochemistry, 145
Catalase, 200
CDNA cloning, 226
Cell multiplication, 330
Chemoembolization, 181
Cholestasis, 22
–, 70
–, 120
–, 290
Chronic acute hepatitis, 322
Chronic delta hepatitis, 102
Chronic non-A, non-B hepatitis, 77
Chronic persistent hepatitis, 29
Cirrhosis, 65
–, 92
–, 206
–, 257
–, 297
Collagen, 206
Colon carcinoma cell line, 53
Cyclosporin A, 53
Cystic dilatation of intrahepatic bile duct, 196
Cytochrome *P*-450, 37
Cytokeratin, 8
–, 18
–, 43
–, 232
Cytokine, 367
Cytoskeleton, 232

Desmin, 206
Direct sequencing, 374
Disease relapse, 322
Drug metabolism, 37
Drug-induced hepatitis, 318
Drug-induced liver injury, 65
–, 272

Electron microscopy, 172
Embolization-therapeutic, 181
Encephalopathy, 92
Endotoxaemia, 263
Endotoxin, 359
–, 367
Enzyme assay, 200
Estrogen, 287
Extracellular matrix, 43
–, 206

Faecal biotransformation, 111
Fat-storing cell, 302
Fine needle, 344
Free oxygen radical scavenger enzyme, 200
Functional renal failure, 263

Galactose, 22
Genetic, 385
Glucagon, 92
Glucose, 22
–, 92
Gluthathione peroxidase, 200

Hamster, 111
HBV chronic infection, 374
HBV replication, 29
–, 102
HDV RNA, 102
Hemochromatosis, 172
Hemodialysis, 385
Hemorrhage, 70
Hepatectomy, 53
Hepatic blood flow, 189
Hepatic clearance, 189
–, 215
Hepatic encephalopathy, acute, 133
Hepatic encephalopathy, chronic, 133
Hepatic microcirculation, 313
Hepatitis B e antigen, 29
Hepatitis B surface antigen, 29
Hepatitis B vaccine, 385
Hepatitis B, virus, 124
–, 326
Hepatitis B virus markers, 385
Hepatitis C virus, 77
–, 124
–, 318
Hepatitis D, 124
Hepatitis, 232
Hepatocellular carcinoma, 181
–, 297
–, 349
Hepatocyte, 330
Hepatoma, 181
–, 287
Hepatorenal syndrome, 153
–, 263
Histologic deterioration, 29
HLA, 9
–, 385
Hormonal treatment, 297
Human gastric mucosa, 65
Human peripheral blood lymphocyte, 326
Hyodexoycholic acid, 111
Hyperbilirubinaemia, 159

Icterus, 159
IGF-II, 226
Immunodeficiency, 385
Immunohistochemistry, 43
–, 206
Immunohistology, 374
Immunosuppression, 53
–, 102
Inflammatory bowel disease, 120
Insulin, 92
Interferon, α,77
Interleukin-1, 359
Intraarterial chemotherapy, 349
Intrinsic clearance, 189
Iron, 172
Isolated liver perfusion, 313
Ito cell, 330

Kupffer cell, 367

Latency, 374
Leukotriene E, 263
Lipiodol, 349
Lipocyte, 206
Lipoprotein, 290
Lithocolate, 313
Liver, 43
–, 172
–, 206
–, 344
Liver biopsy specimen, 200
Liver cancer, 287
–, 297

0168-8278/90/$03.50 © 1990 Elsevier Science Publishers B.V. (Biomedical Division)

Liver cirrhosis, 133
–, 181
–, 290
Liver disease, 37
Liver fibrosis, 43
–, 302
Liver function, 92
Liver metastasis, 53
Liver neoplasms, 181
Liver transplantation, 9
–, 102
Lysosome, 172

Major histocompatibility complex, 9
Malotilate, 65
Mannitol, 22
–, 215
Mannose, 22
Molecular probe, 102
Morphometry, 145
Mouse, 330
Mouse liver, 145
Murocholic acid, 111
Myofibroblast, 206

Nitrogen balance, 92
Nitroglycerin, 189
Non-cirrhotic portal hypertension, 80
Non-malignant diseased human liver, 200
Northern blot, 226
Nutrition disorder, 133
Nutritional status, 92

Oral adjuvant, 326
Orthostatic reflex, 70

Paramyxovirus, 367
PCR, 374
Penicillamine, D322
Perfused liver, 22
Periportal fibrosis, 313
Peroxisome, 145
Phenprocoumon, 318
Polyclonal IgG, 326
Polymerase chain reaction, 124
Portal blood flow, 189
Portal hypertension, 257
–, 313
Portal pressure, 189
Portal vascular resistance, 313
Post-transfusion hepatitis, 77
Polythylene glycol, 215
Precore mutant, 374
Prednisolone, 322
Pressor responsiveness, 70
Primary biliary cirrhosis, 16
–, 37
Primary liver cancer, 226
Primary sclerosing cholangitis, 196
Proliferation of bile ductule, 313
Prostaglandin E_2, 65
Prostaglandin, 153
–, 367
Prostanoid, 359
Protein dosage, 226

Randomized double-blind trial, 16
Rat, 53
Reactivation, 374

Secretin, 215
Sensory neuropeptide, 302
Serum ganglioside, 290
Serum hepatitis B virus DNA, 29
Sinusoidal endothelial liver cell, 359
Splanchnic circulation, 257
Sporadic hepatitis, 77
Standard definition, 272
Standard terminology, 272
Starvation, 145
Steroid, 287
Sulfatase, 37
Sulfotransferase, 37
Superoxide dismutase, 200

Taurine, 326
Tenascin, 43
Thyroid hormone, 92
Tissue culture, 330
Total parenteral nutrition, 22
Tumor necrosis factor-α, 367
Tunior necrosis factor, 359

Ultrasound guide, 344
Umbilical vein endothelical cell, 359
Urinary excretion, 263
Ursodeoxycholic acid, 16
–, 165

Vaccine, 326
Viral hepatitis, 145
Virus, 330
Vitamin A, 330